The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 4, pp. 577-581. DOI 10.1345/aph.1C249
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Serio, R. N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Serio, R. N

DRUG INFORMATION ROUNDS

Infliximab Treatment of Sarcoidosis

Ryan N Serio, BSPharm

PharmD Student, St. John's University, 164-40 95 St., Howard Beach, NY 11414-3704, FAX 718/845-3672, E-mail condram{at}msn.com

Reprints: Ryan N Serio BSPharm

OBJECTIVE: To determine whether there is sufficient evidence in the literature to support the use of infliximab in the treatment of sarcoidosis.

DATA SOURCES AND SELECTION: Literature was accessed through MEDLINE (1966-August 2002), OVID (2001-January 2003), and bibliographic searches. Additional databases were also searched. Published literature relevant to the use of infliximab in the treatment of sarcoidosis was evaluated.

DATA SYNTHESIS: In theory, tumor-necrosis factor-{alpha} blockade appears to be an optimal strategy for treating sarcoidosis. Case series reporting the use of infliximab in refractory sarcoidosis was reviewed to evaluate its potential role as a treatment option.

CONCLUSIONS: Although there is insufficient evidence suggesting that infliximab is an appropriate alternative to conventional treatment options as first-line therapy for sarcoidosis, the preliminary outlook on its use in treatment-refractory cases is promising.

Key Words: infliximab, sarcoidosis, tumor necrosis factor

Published Online, March 6, 2003. www.theannals.com, DOI 10.1345/aph.1C249


This article has been cited by other articles:


Home page
 Journal of the American Dental AssociationHome page
L. MANDEL, B. WOLINSKY, and E. C. CHALOM
Treatment of refractory sarcoidal parotid gland swelling in a previously reported unresponsive case
J Am Dent Assoc, September 1, 2005; 136(9): 1282 - 1285.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
E W Lindstedt, G S Baarsma, R W A M Kuijpers, and P M van Hagen
Anti-TNF-{alpha} therapy for sight threatening uveitis
Br. J. Ophthalmol., May 1, 2005; 89(5): 533 - 536.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
E C Keystone
The utility of tumour necrosis factor blockade in orphan diseases
Ann Rheum Dis, November 1, 2004; 63(suppl_2): ii79 - ii83.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.